Thane: Bajaj Healthcare Limited, a manufacturer of APIs, Intermediates and Formulations has recently announced the launch of API and Formulation of "DGJAJ" (2-Deoxy-D-Glucose), an antiviral drug used for treating COVID patients, in collaboration with Defence Research and Development Organisation (DRDO). BHL had received a license agreement from DRDO on 7th July, 2021, to manufacture...
Thane: Bajaj Healthcare Limited, a manufacturer of APIs, Intermediates and Formulations has recently announced the launch of API and Formulation of "DGJAJ" (2-Deoxy-D-Glucose), an antiviral drug used for treating COVID patients, in collaboration with Defence Research and Development Organisation (DRDO). BHL had received a license agreement from DRDO on 7th July, 2021, to manufacture and market 2-Deoxy-D-Glucose (2-DG).
"The production of "DGJAJ" commenced from today onwards," the company said in a filing on Saturday.
2-Deoxy-D-glucose (2-DG) is a glucose analogue, which has the 2-hydroxyl group replaced by hydrogen. 2-DG is transported in cells by the glucose transporters on the cell membrane but it cannot undergo further glycolysis and act as inhibitor of glycolysis. Therefore, cells with higher glucose uptake, for example tumour cells, virally infected cells, inflammatory cells have also a higher uptake of 2-DG. Since, it accumulates selectively more in such cells with high glucose demand; it offers an attractive approach of inhibiting tumour cell growth, viral infection and inflammation.
2-Deoxy-D-Glucose (2-DG) helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence. The drug works by selectively accumulating in the virusinfected cells and prevents virus growth by stopping viral synthesis and energy production. It can be administered only upon prescription and under the supervision of a qualified physician to hospitalised moderate to severe COVID-19 patients as an adjunct therapy to the existing standard of care.
The drug comes in powder form in a sachet, which is taken orally by dissolving it in water. Its selective accumulation in virally infected cells makes this drug unique.
Commenting on the announcement, Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare said "We are pleased to commence the production of 2-Deoxy-D-Glucose under our brand name "DGJAJ", after receiving license from DRDO. We are quite delighted to add yet another product in our product portfolio. This product will further help us in growing our formulation business. Health experts are anticipating a 3rd wave of COVID-19, which may be even more severe as the virus has undergone several mutations over the time. We hope the availability of an effective treatment such as 2-Deoxy-D-Glucose (2-DG) will offer patients with much needed and timely therapy option. Most patients ailing from moderate to severe symptoms can benefit from the use of 2-Deoxy-D-Glucose."
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd